Key points from article :
MUVON Therapeutics, a clinical-stage biotech company specializing in skeletal muscle regeneration, has reached a critical milestone in its phase 2 clinical trial for treating stress urinary incontinence (SUI), a condition affecting over 200 million women worldwide. Interim data from the SUISSE MPC2 study showed promising safety and efficacy results for the company’s Muscle Precursor Cell (MPC)-based therapy. The international Data Safety Monitoring Board has recommended the continuation of the study, with final results expected in Q3 2025.
The trial evaluates how well MUVON’s engineered tissue product restores urethral sphincter muscle function, aiming to provide a novel treatment option for patients with limited alternatives. CEO Deana Mohr highlighted the company’s progress and upcoming participation in the 2025 J.P. Morgan Healthcare Conference, where they will share development strategies and seek investment partnerships to support their growth goals.
